NEW YORK, April 19, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conatus Pharmaceuticals Inc. CNAT, MasTec, Inc. MTZ, Cyclacel Pharmaceuticals, Inc. CYCC, Melinta Therapeutics, Inc. MLNT, North American Construction Group Ltd. NOA, and B.O.S. Better Online Solutions BOSC, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
CNAT DOWNLOAD: http://Fundamental-Markets.com/register/?so=CNAT
MTZ DOWNLOAD: http://Fundamental-Markets.com/register/?so=MTZ
CYCC DOWNLOAD: http://Fundamental-Markets.com/register/?so=CYCC
MLNT DOWNLOAD: http://Fundamental-Markets.com/register/?so=MLNT
NOA DOWNLOAD: http://Fundamental-Markets.com/register/?so=NOA
BOSC DOWNLOAD: http://Fundamental-Markets.com/register/?so=BOSC
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Conatus Pharmaceuticals Inc. CNAT, MasTec, Inc. MTZ, Cyclacel Pharmaceuticals, Inc. CYCC, Melinta Therapeutics, Inc. MLNT, North American Construction Group Ltd. NOA, and B.O.S. Better Online Solutions BOSC on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
CONATUS PHARMACEUTICALS INC. (CNAT) REPORT OVERVIEW
Conatus Pharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Conatus Pharmaceuticals reported revenue of $7.41MM vs $8.81MM (down 15.85%) and analysts estimated basic earnings per share -$0.12 vs -$0.15. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Conatus Pharmaceuticals reported revenue of $33.59MM vs $35.38MM (down 5.06%) and analysts estimated basic earnings per share -$0.59 vs -$0.61. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.17. The estimated EPS forecast for the next fiscal year is -$0.52 and is expected to report on March 13th, 2020.
To read the full Conatus Pharmaceuticals Inc. (CNAT) report, download it here: http://Fundamental-Markets.com/register/?so=CNAT
-----------------------------------------
MASTEC, INC. (MTZ) REPORT OVERVIEW
MasTec's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, MasTec reported revenue of $1,917.55MM vs $1,602.86MM (up 19.63%) and analysts estimated basic earnings per share $0.40 vs $1.98 (down 79.80%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, MasTec reported revenue of $6,909.42MM vs $6,606.98MM (up 4.58%) and analysts estimated basic earnings per share $3.30 vs $4.29 (down 23.08%). Analysts expect earnings to be released on April 29th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.32. The estimated EPS forecast for the next fiscal year is $4.78 and is expected to report on February 27th, 2020.
To read the full MasTec, Inc. (MTZ) report, download it here: http://Fundamental-Markets.com/register/?so=MTZ
-----------------------------------------
CYCLACEL PHARMACEUTICALS, INC. (CYCC) REPORT OVERVIEW
Cyclacel Pharmaceuticals' Recent Financial Performance
Analysts expect earnings to be released on May 13th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.12. The estimated EPS forecast for the next fiscal year is -$0.80 and is expected to report on March 25th, 2020.
To read the full Cyclacel Pharmaceuticals, Inc. (CYCC) report, download it here: http://Fundamental-Markets.com/register/?so=CYCC
-----------------------------------------
MELINTA THERAPEUTICS, INC. (MLNT) REPORT OVERVIEW
Melinta Therapeutics' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Melinta Therapeutics reported revenue of $35.49MM vs $4.23MM (up 738.79%) and basic earnings per share -$2.97 vs $9,638.72. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Melinta Therapeutics reported revenue of $96.43MM vs $33.86MM (up 184.76%) and analysts estimated basic earnings per share -$17.12 vs -$109.28. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$4.75. The estimated EPS forecast for the next fiscal year is -$5.57 and is expected to report on March 11th, 2020.
To read the full Melinta Therapeutics, Inc. (MLNT) report, download it here: http://Fundamental-Markets.com/register/?so=MLNT
-----------------------------------------
NORTH AMERICAN CONSTRUCTION GROUP LTD. (NOA) REPORT OVERVIEW
North American Construction Group's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, North American Construction Group reported revenue of $99.05MM vs $64.23MM (up 54.22%) and analysts estimated basic earnings per share $0.08 vs $0.08 (down 9.24%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, North American Construction Group reported revenue of $316.36MM vs $225.68MM (up 40.18%) and analysts estimated basic earnings per share $0.47 vs $0.15 (up 204.99%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.28. The estimated EPS forecast for the next fiscal year is $1.36 and is expected to report on February 24th, 2020.
To read the full North American Construction Group Ltd. (NOA) report, download it here: http://Fundamental-Markets.com/register/?so=NOA
-----------------------------------------
B.O.S. BETTER ONLINE SOLUTIONS (BOSC) REPORT OVERVIEW
B.O.S. Better Online Solutions' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, B.O.S. Better Online Solutions reported revenue of $9.09MM vs $7.93MM (up 14.74%) and analysts estimated basic earnings per share $0.11 vs $0.10 (up 10.00%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, B.O.S. Better Online Solutions reported revenue of $32.65MM vs $28.93MM (up 12.85%) and analysts estimated basic earnings per share $0.28 vs $0.24 (up 16.67%). Analysts expect earnings to be released on June 4th, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full B.O.S. Better Online Solutions (BOSC) report, download it here: http://Fundamental-Markets.com/register/?so=BOSC
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Arden Dalio, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
